Hikma Pharmaceuticals Share News (HIK)

BROKER RATINGS SUMMARY: S&P And Shore Upgrade Aviva After Strong Half

LONDON MARKET OPEN: RBS Misses Gains After Swinging To Operating Loss

LONDON MARKET CLOSE: BoE Stimuli Push Up Stocks But Depress Sterling

FTSE rallies after BoE decision, Hikma sinks

* FTSE 100 up 1.6 * BOE cuts interest rates * Hikma slumps after update (Updates prices at close) By Kit Rees and Atul Prakash LONDON, Aug 4 (Reuters) - Britain's top share index rallied after the Bank of England (BoE) cut interest rates on Thursday, although pharmaceuti

FTSE rallies after BoE decision, Hikma sinks

* FTSE 100 up 1.4 * BOE cuts interest rates * Hikma slumps after update (Recasts, adds quote and detail, updates prices) By Kit Rees and Atul Prakash LONDON, Aug 4 (Reuters) - Britain's top share index rallied after the Bank of England (BoE) cut interest rates on Thursda

Broker tips: Johnston Press, Direct Line, Hikma Pharmaceuticals

(ShareCast News) - Johnston Press shares plunged on Thursday as Numis placed its rating and target price 'under review' after the company swung to a first half loss. For the 26 weeks to 2 July, the company posted a statutory pre-tax loss of £183.7m versus a £2.2m profit the year before, as it booked

Citi downgrades Hikma Pharmaceuticals after company´s pre-announcement

(ShareCast News) - Analysts at Citi downgraded their recommendation on shares of Hikma Pharmaceuticals in the wake of the company´s trading update which was issued after the close of trading in London on 3 August. Hikma flagged new drug approvals were arriving more slowly than expected and the phasi

Hikma Pharmaceuticals warns generic drug delays will lower profit

(ShareCast News) - Shares in Hikma Pharmaceuticals plummeted on Thursday after the drugmaker's overnight warning that delays to new US generic products would lower profits. In a trading update for the first six months of the year that was released almost an hour after the London stock market closed

FTSE steadies near 3-week low before BoE decision, Hikma sinks

(ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets) * FTSE 100 steady in morning trade * Focus on BoE's rate decision * Hikma slumps after update By Atul Prakash LONDON,

BROKER RATINGS SUMMARY: RBC Upgrades G4S But Barclays Downgrades It

Hikma says colchicine regulatory approval upheld in US Court of Appeals

(ShareCast News) - Hikma Pharmaceuticals on Thursday said the regulatory approval of its gout medication colchicine has been upheld. The US Court of Appeals for the District of Columbia Circuit affirmed an earlier decision of the US District Court for the District of Columbia, finding in fa

Regulatory Approval Of Hikma's Colchicine Capsule Upheld By US Court

Britain's FTSE climbs to 11-month closing high as insurers rise

(ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets) * FTSE 100 rises 0.5 pct to 6,728.99 points * Healthcare stocks among top gainers * Admiral Group rises after upgrade, L&G up as

Hikma Pharmaceuticals launches generic cancer tablets in US

(ShareCast News) - Hikma Pharmaceuticals said its wholly-owned US affiliate, West-Ward Pharmaceuticals has launched generic cancer treatment tablets in the US. The Capecitabine tablets, which are the generic equivalents to Xeloda tablets, are indicated for adjuvant treatment in patients with Dukes'

WINNERS & LOSERS SUMMARY: Man Group Down As CEO Departs For PIMCO